Ähnliche Pins
Maridebart Cafraglutide's Phase 3 Trial in Atherosclerotic Cardiovascular Disease Reads Out
GESCHÄTZT50 % SICHERHEITin 1,8 JahrenClinicalTrials.gov[1] lists 2028-06-30 as the estimated primary completion date; a sponsor's estimate, and trials of this size routinely slip.Amgen's phase 3 trial of Maridebart Cafraglutide in atherosclerotic cardiovascular disease reaches primary completion, the point at which the last participant's primary outcome is measured. The trial enrolled 12,800 participants. The primary objective of this trial is to demonstrate that maridebart cafraglutide is superior to placebo when given as an adjunct to standard of care with respect to reducing cardiovascular (CV) morbidity and mortality.0.85Maridebart Cafraglutide's Phase 3 Trial in Obesity Reads Out
GESCHÄTZT50 % SICHERHEITin 1,3 JahrenClinicalTrials.gov[1] lists 2027-12-26 as the estimated primary completion date; a sponsor's estimate, and trials of this size routinely slip.Amgen's phase 3 trial of Maridebart Cafraglutide in obesity reaches primary completion, the point at which the last participant's primary outcome is measured. The trial enrolled 3,200 participants. The primary objective of this trial is to evaluate the long-term efficacy, safety, and tolerability of maridebart cafraglutide in participants with obesity or overweight. Trial 20250197 is an extension of trial 20210181 (NCT06858839).0.82Vicadrostat's Phase 3 Trial in Heart Failure Reads Out
GESCHÄTZT50 % SICHERHEITin 1,7 JahrenClinicalTrials.gov[1] lists 2028-05-22 as the estimated primary completion date; a sponsor's estimate, and trials of this size routinely slip.Boehringer Ingelheim's phase 3 trial of Vicadrostat in heart failure reaches primary completion, the point at which the last participant's primary outcome is measured. The trial enrolled 6,000 participants. This study is open to adults aged 18 or above legal age with heart failure. People can join the study if they have heart failure symptoms and a left ventricular ejection fraction (LVEF) of 40% or more. The purpose of this study is to find out whether vicadrostat (BI 690517) in combination with empagliflozin helps people with heart failure. Participants are put into 2 groups by chance. Every participant has an equal chance of being in each group. The groups are: * Vicadrostat/empagliflozin group: participants take vicadrostat/empagliflozin as tablets once a day. * Placebo/empagliflozin group: participants take placebo/empagliflozin as tablets once a day. Participants can stay in the study as long as they benefit from treatment and can tolerate it. During this time, they visit their doctors regularly. The doctors regularly check participants' health and take note of any unwanted effects. T0.80BI 690517's Phase 3 Trial in Kidney Disease, Chronic Reads Out
GESCHÄTZT50 % SICHERHEITin 1,9 JahrenClinicalTrials.gov[1] lists 2028-08-30 as the estimated primary completion date; a sponsor's estimate, and trials of this size routinely slip.Boehringer Ingelheim's phase 3 trial of BI 690517 in kidney disease, chronic reaches primary completion, the point at which the last participant's primary outcome is measured. The trial enrolled 11,000 participants. This study is open to adults with chronic kidney disease at risk of progression. People with and without type 2 diabetes can take part in this study. The study is open to people who take other medicines called angiotensin converting enzyme inhibitors (ACEi) or angiotensin receptor blockers (ARB). People who already take empagliflozin or any other sodium-glucose cotransporter-2 inhibitor (SGLT2i) can also join. The study is also open to people who currently do not take any of these treatments. The purpose of this study is to find out whether a medicine called BI 690517 helps people with chronic kidney disease when taken in combination with a study medicine called empagliflozin. Worsening of kidney function increases the risk for kidney failure, cardiovascular disease, and heart failure hospitalisation. After a run-in period, during which participants are confirmed to be receiving clinical0.76BGF MDI 320/14.4/9.6 μG's Phase 3 Trial in COPD Reads Out
GESCHÄTZT50 % SICHERHEITin 1,2 JahrenClinicalTrials.gov[1] lists 2027-12-03 as the estimated primary completion date; a sponsor's estimate, and trials of this size routinely slip.AstraZeneca's phase 3 trial of BGF MDI 320/14.4/9.6 μG in copd reaches primary completion, the point at which the last participant's primary outcome is measured. The trial enrolled 5,000 participants. This study will evaluate the effect of triple ICS/LAMA/LABA therapy with BGF MDI 320/14.4/9.6 μg on cardiopulmonary outcomes relative to LAMA/LABA therapy with GFF MDI 14.4/9.6 μg in a population with COPD and elevated cardiopulmonary risk.0.75Enicepatide's Phase 3 Trial in Obesity or Overweight Reads Out
GESCHÄTZT50 % SICHERHEITin 1,8 JahrenClinicalTrials.gov[1] lists 2028-07-24 as the estimated primary completion date; a sponsor's estimate, and trials of this size routinely slip.Roche's phase 3 trial of Enicepatide in obesity or overweight reaches primary completion, the point at which the last participant's primary outcome is measured. The trial enrolled 2,000 participants. The purpose of this study is to assess the efficacy and safety of enicepatide, a dual glucagon like peptide-1 (GLP-1)/glucose-dependent insulinotropic polypeptide (GIP) receptor agonist (RA), at multiple doses compared with placebo for weight management in participants without Type 2 diabetes mellitus (T2DM) who have obesity or overweight with at least one weight-related comorbidity.0.74Elecoglipron's Phase 3 Trial in Type 2 Diabetes Mellitus Reads Out
GESCHÄTZT50 % SICHERHEITin 1,8 JahrenClinicalTrials.gov[1] lists 2028-07-05 as the estimated primary completion date; a sponsor's estimate, and trials of this size routinely slip.AstraZeneca's phase 3 trial of Elecoglipron in type 2 diabetes mellitus reaches primary completion, the point at which the last participant's primary outcome is measured. The trial enrolled 2,000 participants. The purpose of this study is to evaluate the efficacy, safety, and tolerability of elecoglipron and dapagliflozin in combination, compared with elecoglipron alone and dapagliflozin alone, in adults with type 2 diabetes mellitus (T2DM) inadequately managed with lifestyle management alone or treated with other background glucose-lowering medication.0.74Elecoglipron's Phase 3 Trial in Weight Management Reads Out
GESCHÄTZT50 % SICHERHEITin 1,9 JahrenClinicalTrials.gov[1] lists 2028-07-31 as the estimated primary completion date; a sponsor's estimate, and trials of this size routinely slip.AstraZeneca's phase 3 trial of Elecoglipron in weight management reaches primary completion, the point at which the last participant's primary outcome is measured. The trial enrolled 4,500 participants. This master study protocol, Study D7260C00015, covers 2 independent, pivotal studies, Study 1 and Study 2. Each study is a global, randomized, double-blind, parallel-group, multicenter, Phase III study to assess the efficacy and safety of elecoglipron compared with placebo adjunct to diet and exercise for weight management, in adults living with obesity or overweight with at least one weight-related comorbidity, and without T2DM (Study 1) or with T2DM (Study 2).0.73Camizestrant's Phase 3 Trial in Breast Cancer, Early Breast Cancer Reads Out
GESCHÄTZT50 % SICHERHEITin 209 TagenClinicalTrials.gov[1] lists 2027-04-20 as the estimated primary completion date; a sponsor's estimate, and trials of this size routinely slip.AstraZeneca's phase 3 trial of Camizestrant in breast cancer, early breast cancer reaches primary completion, the point at which the last participant's primary outcome is measured. The trial enrolled 4,300 participants. This is a Phase III open-label study to assess if camizestrant improves outcomes compared to standard endocrine therapy in patients with ER+/HER2 - early breast cancer with intermediate or high risk for disease recurrence who completed definitive locoregional therapy (with or without chemotherapy) and standard adjuvant endocrine therapy (ET) for at least 2 years and up to 5 years. The planned duration of treatment in either arm of the study is 60 months.0.72Cagrisema's Phase 3 Trial in Obesity Reads Out
GESCHÄTZT50 % SICHERHEITin 1,4 JahrenClinicalTrials.gov[1] lists 2028-02-23 as the estimated primary completion date; a sponsor's estimate, and trials of this size routinely slip.Novo Nordisk's phase 3 trial of Cagrisema in obesity reaches primary completion, the point at which the last participant's primary outcome is measured. The trial enrolled 2,500 participants. This clinical study is testing how the study medicine CagriSema helps people living with obesity, with or without type 2 diabetes (T2D), lose weight. The purpose of the study is to find out how safe and effective CagriSema is for body weight loss in these participants. Participants will receive either CagriSema or semaglutide, and which treatment participants receive is decided by chance. CagriSema is a new study medicine being tested, while semaglutide is a medicine that doctors can already prescribe. The study will last for about 83 weeks0.72Tozorakimab's Phase 3 Trial in Viral Lung Infection and Acute Respiratory Failure Reads Out
GESCHÄTZT50 % SICHERHEITin 1,1 JahrenClinicalTrials.gov[1] lists 2027-11-04 as the estimated primary completion date; a sponsor's estimate, and trials of this size routinely slip.AstraZeneca's phase 3 trial of Tozorakimab in viral lung infection and acute respiratory failure reaches primary completion, the point at which the last participant's primary outcome is measured. The trial enrolled 3,527 participants. The purpose of this study is to evaluate the effect of tozorakimab, as an add-on to SoC in patients with viral lung infection requiring supplemental oxygen, on the prevention of death or progression to IMV/ECMO.0.71REGN7508's Phase 3 Trial in Venous Thromboembolism Reads Out
GESCHÄTZT50 % SICHERHEITin 150 TagenClinicalTrials.gov[1] lists 2027-02-20 as the estimated primary completion date; a sponsor's estimate, and trials of this size routinely slip.Regeneron Pharmaceuticals's phase 3 trial of REGN7508 in venous thromboembolism reaches primary completion, the point at which the last participant's primary outcome is measured. The trial enrolled 2,000 participants. This study is researching an experimental drug called REGN7508 (called "study drug"). The study is focused on adults undergoing elective, unilateral (one side) total knee replacement surgery. The aim of the study is to see how effective the study drug is at preventing Venous Thromboembolism (VTE) and other related diseases after total knee replacement surgery. The study is looking at several other research questions, including: * What side effects may happen from taking the study drug * How much study drug is in the blood at different times * Whether the body makes antibodies against the study drug (which could make the study drug less effective or could lead to side effects)0.70
Boehringer Ingelheim